Hata M. et al. [38], in PCV or AMD patients treated with ranibizumab, did not find any pharmacogenetic association, but, regarding PCV patients only, they found ARMS2 A69S (rs10490924) to be related with visual acuity at baseline and 12 months, although not with visual prognosis. Here, ARMS2 is linked to age-related macular degeneration.